Hrt Financial LP Replimune Group, Inc. Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$5.01 - $9.46 $925,652 - $1.75 Million	184,761 New	184,761 $1.66 Million
Q2 2023 Aug 11, 2023	BUY	$15.65 - $24.1 $1.82 Million - $2.81 Million	116,469 New	116,469 $2.7 Million
Q4 2022 Feb 10, 2023	BUY	$17.09 - $27.91 $759,428 - $1.24 Million	44,437 New	44,437 $1.21 Million
Q1 2022 May 16, 2022	SELL	$15.24 - $29.75 $528,873 - $1.03 Million	-34,703 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$25.43 - $34.25 $882,497 - $1.19 Million	34,703 New	34,703 $940,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.